scout
Opinion|Videos|August 22, 2024

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Episodes in this series

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: BTKi degraders

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME